What a defined fragment length means

Our target fragments are 20 to 80 base pairs. Here is why the range matters more than the number.

When people ask what is different about our PDRN, the shortest answer is a range: 20 to 80 base pairs, roughly 13 to 53 kilodaltons. PDRN described in the scientific literature commonly spans a far wider range. The difference is not that ours is smaller. It is that ours is defined.

A defined range means a batch can be characterised and compared. Two batches made months apart can be laid side by side and asked the same question: do the fragments fall where they should? If the answer is yes, the rest of the work, tolerability testing, formulation, the studies to come, is built on material that behaves the same way each time.

Getting there is a matter of method rather than luck. We extract the DNA, purify it and bring it to the range, and we have developed our own methods around each of the three steps. The last step is where the range is made, but the first two decide whether it can be made cleanly at all. Plant cells are among the hardest biological sources to open, which is one reason few people have tried.

None of this establishes what the material does in people. Our most advanced programme is preclinical, and no Synthena medicine has been approved for any indication. A defined length is a promise about consistency, not about outcome. It is the promise that has to come first.

About Synthena Pharmaceuticals

Synthena Pharmaceuticals Limited is a pharmaceutical company founded in Hong Kong in July 2026 and focused on one substance, PDRN. Its aim is to turn PDRN into medicines made without animal-derived sources, produced within a defined fragment-length range and studied across five fields of human biology. Its most advanced programme is preclinical; no Synthena medicine has entered clinical trials or been approved for any indication.

This page describes research and development. It does not establish the safety or efficacy of any Synthena medicine.